Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.

Autor: Boustani M; Division of Internal Medicine and Geriatrics, Indiana University School of Medicine, Indianapolis, IN, USA., Doty EG; Lilly Corporate Center, Indianapolis, IN, 46285, USA., Garrison LP Jr; Department of Pharmacy, The CHOICE Institute, University of Washington, Seattle, WA, USA., Smolen LJ; Medical Decision Modeling Inc, Indianapolis, IN, USA., Klein TM; Medical Decision Modeling Inc, Indianapolis, IN, USA., Murphy DR; Medical Decision Modeling Inc, Indianapolis, IN, USA., Spargo AW; Lilly Corporate Center, Indianapolis, IN, 46285, USA., Belger M; Eli Lilly and Company, Bracknell, UK., Johnston JA; Lilly Corporate Center, Indianapolis, IN, 46285, USA. johnston_joseph_a@lilly.com.

Publikováno v: Neurology and therapy [Neurol Ther] 2024 Dec; Vol. 13 (6), pp. 1641-1659. Date of Electronic Publication: 2024 Sep 18.